|
EDMA
3,4-Ethylenedioxy-''N''-methylamphetamine (EDMA) is an entactogen drug of the substituted amphetamine, methamphetamine class. It is an structural analog, analogue of 3,4-methylenedioxy-N-methylamphetamine, MDMA where the methylenedioxy functional group, ring has been replaced by an ethylenedioxy ring. EDMA was first synthesized by Alexander Shulgin. In his book ''PiHKAL'', the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours. According to Shulgin, EDMA produces only mild psychedelic effects consisting of paresthesia, nystagmus, and hypnogogic mental imagery, imagery, with few to no other symptoms. It has been found that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency (pharmacology), potency relative to MDMA, and with negligible effects on dopamine release. However, subsequent research found that EMDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) with values of 117nM for serotonin re ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3,4-Ethylenedioxyamphetamine
3,4-Ethylenedioxyamphetamine (EDA), also known as EDA-6, is a drug of the substituted amphetamine, amphetamine family related to 3,4-methylenedioxyamphetamine (MDA). It is closely related to structural analog, analogues including 3,4-ethylenedioxymethamphetamine (EDMA), 3,4-ethylidenedioxyamphetamine (EIDA), and 3,4-isopropylidenedioxyamphetamine (IDA). EDMA, the ''N''-methyl group, methylated analogue of EDA, is known to be a serotonin–norepinephrine–dopamine releasing agent (SNDRA). According to Alexander Shulgin however, the drug only produced limited psychoactive drug, psychoactive effects in humans at doses in the range of 150 to 250mg. See also * 3,4-Ethylenedioxymethamphetamine (EDMA) * 3,4-Ethylenedioxymethcathinone (EDMC) * 3,4-Ethylidenedioxyamphetamine (EIDA) * 3,4-Isopropylidenedioxyamphetamine (IDA) * 3,4-Dimethoxyamphetamine (DMA) References Ethylenedioxyphenethylamines Monoamine releasing agents Substituted amphetamines {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3,4-Ethylenedioxymethcathinone
3,4-Ethylenedioxymethcathinone (EDMC), or 3,4-ethylenedioxy-''N''-methylcathinone, is a monoamine releasing agent (MRA) of the cathinone family related to methylone (3,4-methylenedioxymethcathinone; MDMC). It is the β- keto or cathinone analogue of 3,4-ethylenedioxymethamphetamine (EDMA). EDMC acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). Its values for induction of monoamine release are 347nM for serotonin, 327nM for norepinephrine, and 496nM for dopamine in rat brain synaptosomes. These potencies were about 1.4-fold, 2.2-fold, and 3.7-fold lower than those of methylone, respectively. The drug was first described in 2015, whereas EDMA has been described much earlier. See also * 3,4-Ethylenedioxyamphetamine 3,4-Ethylenedioxyamphetamine (EDA), also known as EDA-6, is a drug of the substituted amphetamine, amphetamine family related to 3,4-methylenedioxyamphetamine (MDA). It is closely related to structural analog, analogues including 3,4-eth ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Substituted Amphetamines
Substituted amphetamines, or simply amphetamines, are a class of compounds based upon the amphetamine structure; it includes all derivative compounds which are formed by replacing, or substituting, one or more hydrogen atoms in the amphetamine core structure with substituents. The compounds in this class span a variety of pharmacological subclasses, including stimulants, empathogens, and hallucinogens, among others. Examples of substituted amphetamines are amphetamine (itself), methamphetamine, ephedrine, cathinone, phentermine, mephentermine, tranylcypromine, bupropion, methoxyphenamine, selegiline, amfepramone (diethylpropion), pyrovalerone, MDMA (ecstasy), and DOM (STP). Some of amphetamine's substituted derivatives occur in nature, for example in the leaves of '' Ephedra'' and khat plants. Amphetamine was first produced at the end of the 19th century. By the 1930s, amphetamine and some of its derivative compounds found use as decongestants in the symptomat ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Substituted Amphetamine
Substituted amphetamines, or simply amphetamines, are a chemical class, class of compounds based upon the amphetamine structure; it includes all derivative (chemistry), derivative compounds which are formed by replacing, or substitution reaction, substituting, one or more hydrogen atoms in the amphetamine core structure with substituents. The compounds in this class span a variety of pharmacological subclasses, including stimulants, Empathogen-entactogen, empathogens, and hallucinogens, among others. Examples of substituted amphetamines are amphetamine (itself), methamphetamine, ephedrine, cathinone, phentermine, mephentermine, tranylcypromine, bupropion, methoxyphenamine, selegiline, amfepramone, amfepramone (diethylpropion), pyrovalerone, MDMA (ecstasy), and 2,5-dimethoxy-4-methylamphetamine, DOM (STP). Some of amphetamine's substituted Derivative (chemistry), derivatives occur in nature, for example in the leaves of ''Ephedra (genus), Ephedra'' and khat plants. Amphetamine w ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PiHKAL
''PiHKAL: A Chemical Love Story'' is a book by Alexander Shulgin and Ann Shulgin published in 1991. The subject of the work is Psychoactive drug, psychoactive phenethylamine Derivative (chemistry), chemical derivatives, notably those that act as psychedelic drug, psychedelics and/or empathogen-entactogens. The main title, PiHKAL, is an acronym that stands for "Phenethylamines I Have Known and Loved". The book is arranged into two parts, the first part being a fictionalized autobiography of the couple and the second part describing 179 different psychedelic compounds (most of which Shulgin discovered himself), including detailed synthesis instructions, bioassays, dosages, and other commentary. The second part was made freely available by Shulgin on Erowid while the first part is available only in the printed text. While the reactions described are beyond the ability of people with a basic chemistry education, some tend to emphasize techniques that do not require difficult-to-ob ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3,4-Ethylidenedioxyamphetamine
3,4-Ethylidenedioxyamphetamine (EIDA) is a substituted derivative of 3,4-methylenedioxyamphetamine (MDA), which was developed by David Nichols and coworkers, in the course of research to determine the bulk tolerance around the benzodioxole portion of the MDA molecule. EIDA was found to produce similar effects to MDA in animals but with less than half the potency, while the isopropylidenedioxy derivative (IPIDA, IDA) did not substitute for MDA and instead had sedative and convulsant effects. This shows limited bulk tolerance at this position and (as with 2C-G-5) makes it likely the activity of EIDA will reside primarily in one enantiomer, although only the racemic mix has been studied as yet. See also * 3,4-Isopropylidenedioxyamphetamine (IDA) * Difluoromethylenedioxyamphetamine (DiFMDA) * F-2 (psychedelic) * 3,4-Ethylenedioxyamphetamine (EIDA) * 3,4-Ethylenedioxymethamphetamine (EDMA) * 3,4-Ethylenedioxymethcathinone 3,4-Ethylenedioxymethcathinone (EDMC), or 3,4-ethyle ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3,4-Isopropylidenedioxyamphetamine
3,4-Isopropylidenedioxyamphetamine (IDA) is a monoamine releasing agent (MRA) of the amphetamine family related to 3,4-methylenedioxyamphetamine (MDA). It is considerably less potent than MDA as an MRA ''in vitro''. IDA fully substituted for MDMA and LSD in animal drug discrimination tests, albeit with 5- to 7-fold lower potency than MDA. See also * 3,4-Ethylidenedioxyamphetamine (EIDA) * 3,4-Ethylenedioxyamphetamine (EDA) * 3,4-Ethylenedioxymethamphetamine (EDMA) * 3,4-Ethylenedioxymethcathinone 3,4-Ethylenedioxymethcathinone (EDMC), or 3,4-ethylenedioxy-''N''-methylcathinone, is a monoamine releasing agent (MRA) of the cathinone family related to methylone (3,4-methylenedioxymethcathinone; MDMC). It is the β- keto or cathinone analog ... (EDMC) References Entactogens Methylenedioxyphenethylamines Monoamine releasing agents Psychedelic phenethylamines Substituted amphetamines {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3,4-methylenedioxy-N-methylamphetamine
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy (tablet form), and molly (crystal form), is an empathogen–entactogenic drug with stimulant and minor psychedelic properties. In studies, it has been used alongside psychotherapy in the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autism spectrum disorder. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours. MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly associated with dance parties, raves, and electronic dance music. Tablets sold as ecstasy may be mixed with other substances such as ephedrine, amphetamine, and methamphetamine. In 2016, about 21 million people between t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonin Releasing Agent
A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A selective serotonin releasing agent (SSRA) is an SRA with less significant or no efficacy in producing neurotransmitter efflux at other types of monoamine neurons, including dopamine and norepinephrine neurons. SRAs, for instance fenfluramine, dexfenfluramine, and chlorphentermine, have been used clinically as appetite suppressants. However, these SRAs were withdrawn from the market due to toxicity in the 1990s and no SRAs were available or employable for clinical study for many years. In any case, a low-dose formulation was reintroduced for treatment of Dravet syndrome in 2020 and this allowed clinical and research use of SRAs in humans once again. Aside from use as appetite suppressants, SSRAs have been proposed as novel antidepressants and anxiolytics, with the potential for a faster onset of action and superior effectiveness relative to the selectiv ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these designer drugs were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human tr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Dopamine
Dopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. It is an organic chemical of the catecholamine and phenethylamine families. It is an amine synthesized by removing a carboxyl group from a molecule of its precursor chemical, L-DOPA, which is synthesized in the brain and kidneys. Dopamine is also synthesized in plants and most animals. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controllin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
